BEIJING, June 29,
2022 /PRNewswire/ -- Infobird Co., Ltd (NASDAQ: IFBD)
("Infobird" or the "Company"), a leading provider of AI-powered
customer engagement solutions in China, today announced that it has started to
provide services to a leading global pharmaceutical and vaccine
manufacturer's subsidiary with operations in China. Under this cooperation, Infobird will
leverage its AI Chatbots and experience in the healthcare industry
to provide dedicated support for the client's digital and
intelligent customer engagement initiative designed to support the
client's patient notification process for vaccines including
COVID-19, HPV and various childhood vaccines.
As one of the world's leading professional human vaccine
development and production companies, this manufacturer has always
been committed to producing high quality and safe vaccines so that
more children and families are protected by immunization.
Infobird's AI Chatbot SaaS product can empower the vaccine
manufacturer to provide customers with professional, attentive and
convenient vaccination notification services, and therefore
comprehensively improve the number of vaccinations and promote the
development of preventive immunization. This cooperation is an
important step for Infobird to, for the first time, formally
provide its AI chatbot to a client to improve patient vaccination
notification.
According to Vernoster Sullivan, the global vaccine market size
increased from USD 27.5 billion in
2016 to USD 36.5 billion in 2020,
accounting for 2.8% of the total global pharmaceutical market, with
a CAGR of 7.3%. With increasing vaccine awareness among the
population in low- and middle-income countries and rising vaccine
penetration, the global vaccine market is expected to reach
USD 80.9 billion and USD 136.7 billion by 2025 and 2031, with a CAGR
of 17.3% and 9.1%.
In recent years, the share of vaccine products in China's pharmaceutical market has been on the
rise. Driven by favorable government policies, technological
innovation in vaccines and increased awareness of vaccination, the
China vaccine market has increased
from RMB27.1 billion in 2016 to
RMB75.3 billion in 2020, at a CAGR of
29.10%, and is expected to reach RMB383.5
million in 2031. The market is expected to reach
RMB 383.5 million by 2031, growing at
a CAGR of 15.95% from 2020 to 2031. China has now become the second largest
vaccine market in the world making it essential to optimize the
customer service process through digital transformation, expand the
market share of Chinese vaccines and improve the customer
experience so vaccine R&D and manufacturing companies can
better promote and support the patient benefits of
immunization.
Under this cooperation, Infobird's intelligent outbound
call solution primarily includes AI Chatbot outbound call, which
will be responsible for the client's vaccination notification, such
as COVID-19 vaccine, HPV vaccine, and various childhood vaccines.
The entire process is operated by AI without human involvement,
which can help to reduce the staff's burden while improving
customer experience and helping the client to increase the
vaccination rate. At the same time, since vaccines are one of the
most effective measures to prevent and control the COVID-19
epidemic at present, utilizing Infobird's intelligent outbound call
method is expected to help the client to notify users of the second
and third doses of COVID-19 vaccine in advance, which is expected
to largely increase the number of COVID-19 vaccinations for the
client.
The service Infobird provides to the client is expected to
take place in three phases, with the first phase focusing on
intelligent outbound calling for some hospitals/health clinics in
several provinces in China. The
second and third phases are expected to continue to expand the
geographic territory.
As a leading AI SaaS software provider in China, Infobird is committed to making
enterprise customer engagement development more personalized and
intelligent. Infobird's solutions for the healthcare industry have
been applied in many large leading enterprises such as the
healthcare brand Taikang Health Investment, and cover multiple
business scenarios such as customer service, helping enterprises to
promote the digital transformation of customer interaction, improve
customer experience, and thus achieve cost reduction and
efficiency. In the future, the healthcare industry will continue to
be a key area of focus for Infobird, and the company will continue
to promote intelligent standard SaaS products and technologies
according to market demand, penetrate digitalization into more
healthcare service scenarios, and continue to energize the
development of the healthcare economy with intelligent
technologies.
About Infobird Co., Ltd
Infobird, headquartered in Beijing,
China, is a software-as-a-service provider of innovative
AI-powered, or artificial intelligence enabled, customer engagement
solutions in China. For more
information, visit Infobird's website at www.Infobird.com.
Forward-Looking Statements
This press release contains certain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. Words such as "will, "future," "expects," "believes," and
"intends," or similar expressions, are intended to identify
forward-looking statements. Statements that are not historical
facts, including statements about the Company's beliefs and
expectations, are forward-looking statements. All forward-looking
statements are inherently uncertain as they are based on current
expectations and assumptions concerning future events, results,
conditions or performance of the Company. Readers are cautioned not
to place undue reliance on these forward-looking statements, which
are only predictions and speak only as of the date they are made.
In evaluating such statements, investors and prospective investors
should review carefully various risks and uncertainties and other
matters identified in the Company's filings with the U.S.
Securities and Exchange Commission. These risks and uncertainties
could cause the Company's actual results to differ materially from
those indicated in the forward-looking statements. The Company
undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as may be required by law.
View original
content:https://www.prnewswire.com/news-releases/infobird-co-ltd-provides-digital-and-intelligent-customer-engagement-solution-to-enhance-patient-vaccination-notification-services-for-a-top-10-global-pharmaceutical-companys-subsidiary-301577803.html
SOURCE INFOBIRD